Aly‐Khan A. Lalani

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma

Aly‐Khan A. Lalani, Wanling Xie, Dylan J. Martini et al. · Journal for ImmunoTherapy of Cancer · 2018 · 256 citations · Full text

Metabolomic adaptations and correlates of survival to immune checkpoint blockade

Haoxin Li, Kevin Bullock, Carino Gurjao et al. · Nature Communications · 2019 · 217 citations · Full text

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma

Rana R. McKay, Dominick Bossé, Wanling Xie et al. · Cancer Immunology Research · 2018 · 134 citations · Full text

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 126 citations · Full text